Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 12 October 2004
Vol. 2004, Issue 254, p. tw365
[DOI: 10.1126/stke.2542004tw365]


CANCER Another Notch for Targeted Therapy?

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer that typically affects children and adolescents. Although the current cure rate is high, T-ALL patients must endure intensive regimens of highly cytotoxic chemotherapy, so there is great interest in developing targeted therapies with fewer side effects. Weng et al. now report that ~50% of T-ALLs have activating mutations in the gene encoding NOTCH1, a transmembrane receptor that regulates T cell differentiation. Together with previous evidence implicating NOTCH1 in cancer development, these results raise the possibility that inhibitors of NOTCH signaling, including the {gamma}-secretase inhibitors, a group of drugs currently being developed for Alzheimer's disease, may merit investigation as anticancer agents.

A. P. Weng, A. A. Ferrando, W. Lee, J. P. Morris, L. B. Silverman, C. Sanchez-Irizarry, S. C. Blacklow, A. T. Look, J. C. Aster, Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004). [Abstract] [Full Text]

Citation: Another Notch for Targeted Therapy? Sci. STKE 2004, tw365 (2004).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882